[Skip to Navigation]
March 2002

Treatment Considerations While Awaiting the Ideal Bullous Pemphigoid Trial

Author Affiliations

Not Available

Arch Dermatol. 2002;138(3):404. doi:10.1001/archderm.138.3.404

THE SEARCH for an effective and safe therapy for bullous pemphigoid (BP) is important. Compared with other cutaneous disorders, BP has a relatively high morbidity and may occasionally be fatal. It most frequently affects the elderly, who are especially susceptible to the adverse effects of systemic drugs such as corticosteroids. The first-line agents that are used by most dermatologists are systemic corticosteroids. In mild cases of BP, there is a tendency to use potent topical steroids or anti-inflammatory agents other than corticosteroids, such as oral antibiotics, nicotinamide, or dapsone. In rare instances, nonsteroidal immunosuppressive therapy is instituted.

Add or change institution